IP Library › Granted Patent US 8,063,020
Granted Patent B2
US 8,063,020 · App. 12/314,737 · Granted Nov 22, 2011

Resuscitation fluid

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,063,020
App. No.
12/314,737
Granted
Nov 22, 2011
Kind
B2
Abstract

A method for treating conditions related to lack of blood supply with a lipid based resuscitation fluid is disclosed. The resuscitation fluid contains a lipid component and an aqueous carrier. The lipid component forms an emulsion with the aqueous carrier. The resuscitation fluid can be used to increase the blood pressure and to carry oxygen to tissues. The resuscitation fluid can also be used for preserving the biological integrity of donor organs for transplantation.

Claims (26)

1. A method for treating hemorrhagic shock in a human or animal subject, comprising:

administering to said subject an effective amount of a lipid based resuscitation fluid comprising a lipid component and an aqueous carrier, wherein said lipid component forms an emulsion with said aqueous carrier in the form of lipid micelles with a polar outer surface and an inner hydrophobic space.

2. The method of claim 1 , wherein said hemorrhagic shock is severe hemorrhagic shock.

3. The method of claim 1 , wherein said resuscitation fluid further comprises a plasma component.

4. The method of claim 3 , wherein said plasma component is albumin.

5. The method of claim 4 , wherein said albumin has a final concentration of approximately 5% (w/v).

6. The method of claim 1 , wherein said resuscitation fluid further comprises at least one additive selected from the group consisting of oncotic agents, crystalloid agents, buffering agents, carbohydrates, salts, vitamins, antibodies, and surfactants.

7. The method of claim 1 , wherein said resuscitation fluid further comprises a buffering agent.

8. The method of claim 7 , wherein said buffering agent comprises histidine at a concentration of between 0.01M to 0.2M.

9. The method of claim 1 , further comprising:

oxygenating the lipid based resuscitation fluid prior to administration to said subject.

10. The method of claim 9 , wherein said lipid based resuscitation fluid is oxygenated by bubbling an oxygen-containing gas through the lipid based resuscitation fluid for 1 to 5 minutes.

11. The method of claim 9 , wherein said lipid based resuscitation fluid is oxygenated by bubbling a gas comprising 90%-100% (v/v) oxygen through the lipid based resuscitation fluid for about 1 minute.

12. The method of claim 1 , wherein said resuscitation fluid is administered either intravenously or intra-arterially.

13. The method of claim 1 , wherein said resuscitation fluid is prepared by mixing said lipid component with said aqueous carrier to form said emulsion.

14. A method for treating hemorrhagic shock in a human or animal subject, comprising:

administering to said subject an effective amount of a lipid based resuscitation fluid consisting essentially of:

a lipid component;

a polar liquid carrier; and

at least one additive selected from the group consisting of oncotic agents, crystalloid agents, buffering agents, carbohydrates, salts, vitamins, amino acids, vessel expanders, antibodies, and surfactants,

wherein said lipid component forms an emulsion with said a polar liquid carrier in the form of lipid micelles with a polar outer surface and an inner hydrophobic space.

15. The method of claim 14 , wherein said hemorrhagic shock is severe hemorrhagic shock.

16. A method for treating hemorrhagic shock in a human or animal subject, comprising:

administering to said subject an effective amount of a lipid based resuscitation fluid comprising a lipid component and an aqueous carrier,

wherein said lipid component forms an emulsion with said aqueous carrier in the form of lipid micelles with a polar outer surface and an inner hydrophobic space and wherein said emulsion is administered into said subject without further encapsulation.

17. The method of claim 16 , wherein said hemorrhagic shock is severe hemorrhagic shock.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2015
From: SIMPKINS, CUTHBERT O.
To: VIVACELLE BIO, INC.
Reel/Frame 035588/0864 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2014
From: SIMPKINS, CUTHBERT O.
To: VIVACELLE BIO, INC.
Reel/Frame 033791/0481 →
Continuity (3)
Provisional Application 61016443 · Dec 22, 2007
Provisional Application 61064639 · Mar 18, 2008
Related Publication 20090163418A1 · Jun 25, 2009